→
Eli Lilly is positioned for significant upside, evidenced by a staggering 128.83% year-over-year EPS growth and a revenue growth of 47.44% over the same period. With a current price of $1004.92, which is approximately 11.4% below its 52-week high of $1133.95, the stock offers a compelling entry point for investors. The company's strong fundamentals, including a 101.31% ROE and a solid analyst consensus with 11 Strong Buy ratings, further solidify its growth potential.
Investors should consider adding Eli Lilly to their portfolios, given its strong growth trajectory and robust earnings performance.
Eli Lilly's Q1 2026 earnings beat estimates by a significant margin, reporting $8.55 against an estimate of $6.73, showcasing its robust performance. Furthermore, with a current ratio of 1.50, the company is well-positioned to meet its short-term liabilities, enhancing its financial stability.
Despite impressive growth metrics, Eli Lilly's P/E ratio of 37.46 suggests that the stock may be overvalued relative to its earnings, particularly if growth slows down. Additionally, with a beta of 0.48, the stock's lower volatility could limit upside potential in a rapidly changing market.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates LLY as Bullish. Investors should consider adding Eli Lilly to their portfolios, given its strong growth trajectory and robust earnings performance.
Despite impressive growth metrics, Eli Lilly's P/E ratio of 37.46 suggests that the stock may be overvalued relative to its earnings, particularly if growth slows down. Additionally, with a beta of 0.48, the stock's lower volatility could limit upside potential in a rapidly changing market.
Eli Lilly's Q1 2026 earnings beat estimates by a significant margin, reporting $8.55 against an estimate of $6.73, showcasing its robust performance. Furthermore, with a current ratio of 1.50, the company is well-positioned to meet its short-term liabilities, enhancing its financial stability.
Eli Lilly is positioned for significant upside, evidenced by a staggering 128.83% year-over-year EPS growth and a revenue growth of 47.44% over the same period. With a current price of $1004.92, which is approximately 11.4% below its 52-week high of $1133.95, the stock offers a compelling entry point for investors. The company's strong fundamentals, including a 101.31% ROE and a solid analyst consensus with 11 Strong Buy ratings, further solidify its growth potential.
Eli Lilly is positioned for significant upside, evidenced by a staggering 128.83% year-over-year EPS growth and a revenue growth of 47.44% over the same period. With a current price of $1004.92, which is approximately 11.4% below its 52-week high of $1133.95, the stock offers a compelling entry point for investors. The company's strong fundamentals, including a 101.31% ROE and a solid analyst consensus with 11 Strong Buy ratings, further solidify its growth potential. Our overall verdict is Bullish.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for LLY at helmterminal.dev/analyze/LLY, updated continuously during US market hours. No signup required.